{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T01:48:40Z","timestamp":1784771320192,"version":"3.55.0"},"reference-count":180,"publisher":"Japan Prosthodontic Society","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Prosthodont Res"],"published-print":{"date-parts":[[2023]]},"DOI":"10.2186\/jpr.jpr_d_22_00238","type":"journal-article","created":{"date-parts":[[2023,2,3]],"date-time":"2023-02-03T22:13:23Z","timestamp":1675462403000},"page":"493-505","source":"Crossref","is-referenced-by-count":11,"title":["Mechanism and clinical use of botulinum neurotoxin in head and facial region"],"prefix":"10.2186","volume":"67","author":[{"given":"Swarnalakshmi","family":"Raman","sequence":"first","affiliation":[{"name":"Department of Stomatognathic Function and Occlusal Reconstruction, Graduate School of Biomedical Sciences, Tokushima University, Tokushima, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumiko","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Bacteriology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitaka","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Stomatognathic Function and Occlusal Reconstruction, Graduate School of Biomedical Sciences, Tokushima University, Tokushima, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshizo","family":"Matsuka","sequence":"additional","affiliation":[{"name":"Department of Stomatognathic Function and Occlusal Reconstruction, Graduate School of Biomedical Sciences, Tokushima University, Tokushima, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"996","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"[1] Erbguth FJ. Historical notes on botulism, Clostridium botulinum, botulinum toxin, and the idea of the therapeutic use of the toxin. Mov Disord. 2004;19(suppl 8):S2\u20136. https:\/\/doi.org\/10.1002\/mds.20003 PMID:15027048","DOI":"10.1002\/mds.20003"},{"key":"2","doi-asserted-by":"crossref","unstructured":"[2] Pirazzini M,Rossetto O,Eleopra R,Montecucco C. Botulinum neurotoxins: biology, pharmacology, and toxicology. Pharmacol Rev. 2017;69:200\u201335. https:\/\/doi.org\/10.1124\/pr.116.012658 PMID:28356439","DOI":"10.1124\/pr.116.012658"},{"key":"3","doi-asserted-by":"crossref","unstructured":"[3] Rossetto O,Pirazzini M,Montecucco C. Botulinum neurotoxins: genetic, structural and mechanistic insights. Nat Rev Microbiol. 2014;12:535\u201349. https:\/\/doi.org\/10.1038\/nrmicro3295 PMID:24975322","DOI":"10.1038\/nrmicro3295"},{"key":"4","doi-asserted-by":"crossref","unstructured":"[4] Lee K,Gu S,Jin L,Le TTN,Cheng LW,Strotmeier J,<i>et al.<\/i> Structure of a bimodular botulinum neurotoxin complex provides insights into its oral toxicity. PLoS Pathog. 2013;9:e1003690. https:\/\/doi.org\/10.1371\/journal.ppat.1003690 PMID:24130488","DOI":"10.1371\/journal.ppat.1003690"},{"key":"5","doi-asserted-by":"crossref","unstructured":"[5] Chen S. Clinical uses of botulinum neurotoxins: current indications, limitations and future developments. Toxins (Basel). 2012;4:913\u201339. https:\/\/doi.org\/10.3390\/toxins4100913 PMID:23162705","DOI":"10.3390\/toxins4100913"},{"key":"6","doi-asserted-by":"crossref","unstructured":"[6] Carruthers A. History of the clinical use of botulinum toxin A and B. Clin Dermatol. 2003;21:469\u201372. https:\/\/doi.org\/10.1016\/j.clindermatol.2003.11.003 PMID:14759577","DOI":"10.1016\/j.clindermatol.2003.11.003"},{"key":"7","doi-asserted-by":"crossref","unstructured":"[7] Pellett S. Learning from the past: historical aspects of bacterial toxins as pharmaceuticals. Curr Opin Microbiol. 2012;15:292\u20139. https:\/\/doi.org\/10.1016\/j.mib.2012.05.005 PMID:22651975","DOI":"10.1016\/j.mib.2012.05.005"},{"key":"8","doi-asserted-by":"crossref","unstructured":"[8] Wan MJ,AlShaker S,Hunter DG. Use of botulinum toxin in ophthalmology. Handb Exp Pharmacol. 2019;263:147\u201360. https:\/\/doi.org\/10.1007\/164_2019_325 PMID:32270340","DOI":"10.1007\/164_2019_325"},{"key":"9","doi-asserted-by":"crossref","unstructured":"[9] Satriyasa BK. Botulinum toxin (Botox) A for reducing the appearance of facial wrinkles: a literature review of clinical use and pharmacological aspect. Clin Cosmet Investig Dermatol. 2019;12:223\u20138. https:\/\/doi.org\/10.2147\/CCID.S202919 PMID:31114283","DOI":"10.2147\/CCID.S202919"},{"key":"10","doi-asserted-by":"crossref","unstructured":"[10] Serrera-Figallo MA,Ruiz-de-Le\u00f3n-Hern\u00e1ndez G,Torres-Lagares D,Castro-Araya A,Torres-Ferrerosa O,Hern\u00e1ndez-Pacheco E,<i>et al.<\/i> Use of botulinum toxin in orofacial clinical practice. Toxins (Basel). 2020;12:112. https:\/\/doi.org\/10.3390\/toxins12020112 PMID:32053883","DOI":"10.3390\/toxins12020112"},{"key":"11","doi-asserted-by":"crossref","unstructured":"[11] Nawrocki S,Cha J. Botulinum toxin: pharmacology and injectable administration for the treatment of primary hyperhidrosis. J Am Acad Dermatol. 2020;82:969\u201379. https:\/\/doi.org\/10.1016\/j.jaad.2019.11.042 PMID:31811879","DOI":"10.1016\/j.jaad.2019.11.042"},{"key":"12","doi-asserted-by":"crossref","unstructured":"[12] Escher CM,Paracka L,Dressler D,Kollewe K. Botulinum toxin in the management of chronic migraine: clinical evidence and experience. Ther Adv Neurol Disord. 2017;10:127\u201335. https:\/\/doi.org\/10.1177\/1756285616677005 PMID:28382110","DOI":"10.1177\/1756285616677005"},{"key":"13","doi-asserted-by":"crossref","unstructured":"[13] Wein T,Esquenazi A,Jost WH,Ward AB,Pan G,Dimitrova R. Onabotulinumtoxin A for the treatment of poststroke distal lower limb spasticity: a randomized trial. PM R. 2018;10:693\u2013703. https:\/\/doi.org\/10.1016\/j.pmrj.2017.12.006 PMID:29330071","DOI":"10.1016\/j.pmrj.2017.12.006"},{"key":"14","doi-asserted-by":"crossref","unstructured":"[14] Poulain B,Molg\u00f3 J,Popoff MR. Clostridial neurotoxins: from the cellular and molecular mode of. The comprehensive sourcebook of bacterial protein toxins. 4th ed. Boston: Academic press; 2015, p 287-336.","DOI":"10.1016\/B978-0-12-800188-2.00011-2"},{"key":"15","unstructured":"[15] Benzon H,Rathmell JP,Wu CL,Turk D,Argoff CE,Hurley RW. Practical Management of Pain. Elsevier Health Sciences E-Book; 2022."},{"key":"16","doi-asserted-by":"crossref","unstructured":"[16] Ayyar BV,Aoki KR,Atassi MZ. The C-terminal heavy-chain domain of botulinum neurotoxin a is not the only site that binds neurons, as the N-terminal heavy-chain domain also plays a very active role in toxin-cell binding and interactions. Infect Immun. 2015;83:1465\u201376. https:\/\/doi.org\/10.1128\/IAI.00063-15 PMID:25624352","DOI":"10.1128\/IAI.00063-15"},{"key":"17","doi-asserted-by":"crossref","unstructured":"[17] Smith TJ,Lou J,Geren IN,Forsyth CM,Tsai R,LaPorte SL,<i>et al.<\/i> Sequence variation within botulinum neurotoxin serotypes impacts antibody binding and neutralization. Infect Immun. 2005;73:5450\u20137. https:\/\/doi.org\/10.1128\/IAI.73.9.5450-5457.2005 PMID:16113261","DOI":"10.1128\/IAI.73.9.5450-5457.2005"},{"key":"18","doi-asserted-by":"crossref","unstructured":"[18] Dunant Y,Isra\u00ebl M. Neurotransmitter release at rapid synapses. Biochimie. 2000;82:289\u2013302. https:\/\/doi.org\/10.1016\/S0300-9084(00)00194-2 PMID:10865118","DOI":"10.1016\/S0300-9084(00)00194-2"},{"key":"19","doi-asserted-by":"crossref","unstructured":"[19] Swaminathan S,Eswaramoorthy S. Structural analysis of the catalytic and binding sites of Clostridium botulinum neurotoxin B. Nat Struct Biol. 2000;7:693\u20139. https:\/\/doi.org\/10.1038\/78005 PMID:10932256","DOI":"10.1038\/78005"},{"key":"20","doi-asserted-by":"crossref","unstructured":"[20] Rummel A. The long journey of botulinum neurotoxins into the synapse. Toxicon. 2015;107:9\u201324. https:\/\/doi.org\/10.1016\/j.toxicon.2015.09.009 PMID:26363288","DOI":"10.1016\/j.toxicon.2015.09.009"},{"key":"21","doi-asserted-by":"crossref","unstructured":"[21] Lobbezoo F,Ahlberg J,Raphael KG,Wetselaar P,Glaros AG,Kato T,<i>et al.<\/i> International consensus on the assessment of bruxism: Report of a work in progress. J Oral Rehabil. 2018;45:837\u201344. https:\/\/doi.org\/10.1111\/joor.12663 PMID:29926505","DOI":"10.1111\/joor.12663"},{"key":"22","unstructured":"[22] American Academy of Sleep Medicine. International Classification of Sleep Disorders. 2nd ed. Diagnostic and Coding Manual. Weschester IL: American Academy of Sleep Medicine; 2005."},{"key":"23","doi-asserted-by":"crossref","unstructured":"[23] Carra MC,Huynh N,Lavigne G. Sleep bruxism: a comprehensive overview for the dental clinician interested in sleep medicine. Dent Clin North Am. 2012;56:387\u2013413. https:\/\/doi.org\/10.1016\/j.cden.2012.01.003 PMID:22480810","DOI":"10.1016\/j.cden.2012.01.003"},{"key":"24","doi-asserted-by":"crossref","unstructured":"[24] Johansson A,Omar R,Carlsson GE. Bruxism and prosthetic treatment: A critical review. J Prosthodont Res. 2011;55:127\u201336. https:\/\/doi.org\/10.1016\/j.jpor.2011.02.004 PMID:21596648","DOI":"10.1016\/j.jpor.2011.02.004"},{"key":"25","doi-asserted-by":"crossref","unstructured":"[25] Guaita M,H\u00f6gl B. Current treatments of bruxism. Curr Treat Options Neurol. 2016;18:10. https:\/\/doi.org\/10.1007\/s11940-016-0396-3 PMID:26897026","DOI":"10.1007\/s11940-016-0396-3"},{"key":"26","doi-asserted-by":"crossref","unstructured":"[26] Lee SJ,McCall WD Jr,Kim YK,Chung SC,Chung JW. Effect of botulinum toxin injection on nocturnal bruxism: a randomized controlled trial. Am J Phys Med Rehabil. 2010;89:16\u201323. https:\/\/doi.org\/10.1097\/PHM.0b013e3181bc0c78 PMID:19855255","DOI":"10.1097\/PHM.0b013e3181bc0c78"},{"key":"27","doi-asserted-by":"crossref","unstructured":"[27] Ivanhoe CB,Lai JM,Francisco GE. Bruxism after brain injury: successful treatment with botulinum toxin-A. Arch Phys Med Rehabil. 1997;78:1272\u20133. https:\/\/doi.org\/10.1016\/S0003-9993(97)90343-9 PMID:9365360","DOI":"10.1016\/S0003-9993(97)90343-9"},{"key":"28","doi-asserted-by":"crossref","unstructured":"[28] Pidcock FS,Wise JM,Christensen JR. Treatment of severe post-traumatic bruxism with botulinum toxin-A: case report. J Oral Maxillofac Surg. 2002;60:115\u20137. https:\/\/doi.org\/10.1053\/joms.2002.29127 PMID:11757023","DOI":"10.1053\/joms.2002.29127"},{"key":"29","doi-asserted-by":"crossref","unstructured":"[29] See SJ,Tan EK. Severe amphethamine-induced bruxism: treatment with botulinum toxin. Acta Neurol Scand. 2003;107:161\u20133. https:\/\/doi.org\/10.1034\/j.1600-0404.2003.02086.x PMID:12580870","DOI":"10.1034\/j.1600-0404.2003.02086.x"},{"key":"30","doi-asserted-by":"crossref","unstructured":"[30] Asutay F,Atalay Y,Asutay H,Acar AH. The evaluation of the clinical effects of botulinum toxin on nocturnal bruxism. Pain Res Manag. 2017;2017:1\u20135. https:\/\/doi.org\/10.1155\/2017\/6264146 PMID:28757802","DOI":"10.1155\/2017\/6264146"},{"key":"31","doi-asserted-by":"crossref","unstructured":"[31] Fern\u00e1ndez-N\u00fa\u00f1ez T,Amghar-Maach S,Gay-Escoda C. Efficacy of botulinum toxin in the treatment of bruxism: systematic review. Med Oral Patol Oral Cir Bucal. 2019;24: e416\u201324. https:\/\/doi.org\/10.4317\/medoral.22923 PMID:31246937","DOI":"10.4317\/medoral.22923"},{"key":"32","doi-asserted-by":"crossref","unstructured":"[32] Kwon KH,Shin KS,Yeon SH,Kwon DG. Application of botulinum toxin in maxillofacial field: part I. Bruxism and square jaw. Maxillofac Plast Reconstr Surg. 2019;41:38. https:\/\/doi.org\/10.1186\/s40902-019-0218-0 PMID:31649901","DOI":"10.1186\/s40902-019-0218-0"},{"key":"33","doi-asserted-by":"crossref","unstructured":"[33] Yurttutan ME,T\u00fct\u00fcnc\u00fcler Sancak K,T\u00fcz\u00fcner AM. Which treatment is effective for bruxism: occlusal splints or botulinum toxin? J Oral Maxillofac Surg. 2019;77:2431\u20138. https:\/\/doi.org\/10.1016\/j.joms.2019.06.005 PMID:31302066","DOI":"10.1016\/j.joms.2019.06.005"},{"key":"34","doi-asserted-by":"crossref","unstructured":"[34] Shim YJ,Lee MK,Kato T,Park HU,Heo K,Kim ST. Effects of botulinum toxin on jaw motor events during sleep in sleep bruxism patients: a polysomnographic evaluation. J Clin Sleep Med. 2014;10:291\u20138. https:\/\/doi.org\/10.5664\/jcsm.3532 PMID:24634627","DOI":"10.5664\/jcsm.3532"},{"key":"35","doi-asserted-by":"crossref","unstructured":"[35] Celik D,Mutlu EK. Clinical implication of latent myofascial trigger point. Curr Pain Headache Rep. 2013;17:353. https:\/\/doi.org\/10.1007\/s11916-013-0353-8 PMID:23801006","DOI":"10.1007\/s11916-013-0353-8"},{"key":"36","doi-asserted-by":"crossref","unstructured":"[36] Esenyel M,Caglar N,Aldemir T. Treatment of myofascial pain. Am J Phys Med Rehabil. 2000;79:48\u201352. https:\/\/doi.org\/10.1097\/00002060-200001000-00011 PMID:10678603","DOI":"10.1097\/00002060-200001000-00011"},{"key":"37","doi-asserted-by":"crossref","unstructured":"[37] Bron C,Wensing M,Franssen JLM,Oostendorp RAB. Treatment of myofascial trigger points in common shoulder disorders by physical therapy: A randomized controlled trial [ISRCTN75722066]. BMC Musculoskelet Disord. 2007;8:107. https:\/\/doi.org\/10.1186\/1471-2474-8-107 PMID:17983467","DOI":"10.1186\/1471-2474-8-107"},{"key":"38","doi-asserted-by":"crossref","unstructured":"[38] Borg-Stein J. Treatment of fibromyalgia, myofascial pain, and related disorders. Phys Med Rehabil Clin N Am. 2006;17:491\u2013510, viii. https:\/\/doi.org\/10.1016\/j.pmr.2005.12.003 PMID:16616279","DOI":"10.1016\/j.pmr.2005.12.003"},{"key":"39","doi-asserted-by":"crossref","unstructured":"[39] Chavan P,Raman S,Waskitho A,Dalanon J,Yoshihara Y,Okura K,<i>et al.<\/i> Botulinum toxin injection attenuates nonodontogenic toothache: A case report. Clin Case Rep. 2022;10:e05494. https:\/\/doi.org\/10.1002\/ccr3.5494","DOI":"10.1002\/ccr3.5494"},{"key":"40","doi-asserted-by":"crossref","unstructured":"[40] Ojala T,Arokoski JPA,Partanen J. The effect of small doses of botulinum toxin a on neck-shoulder myofascial pain syndrome: a double-blind, randomized, and controlled crossover trial. Clin J Pain. 2006;22:90\u20136. https:\/\/doi.org\/10.1097\/01.ajp.0000151871.51406.c3 PMID:16340597","DOI":"10.1097\/01.ajp.0000151871.51406.c3"},{"key":"41","doi-asserted-by":"crossref","unstructured":"[41] De Andr\u00e9s J,Adsuara VM,Palmisani S,Villanueva V,L\u00f3pez-Alarc\u00f3n MD. A double-blind, controlled, randomized trial to evaluate the efficacy of botulinum toxin for the treatment of lumbar myofascial pain in humans. Reg Anesth Pain Med. 2010;35:255\u201360. https:\/\/doi.org\/10.1097\/AAP.0b013e3181d23241 PMID:20921836","DOI":"10.1097\/AAP.0b013e3181d23241"},{"key":"42","doi-asserted-by":"crossref","unstructured":"[42] Soares A,Andriolo RB,Atallah AN,da Silva EMK. Botulinum toxin for myofascial pain syndromes in adults. Cochrane Database Syst Rev. 2014;2014:CD007533. PMID:25062018","DOI":"10.1002\/14651858.CD007533.pub3"},{"key":"43","doi-asserted-by":"crossref","unstructured":"[43] Marqu\u00e9s-Mateo M,Puche-Torres M,Iglesias-Gimilio ME. Temporomandibular chronic dislocation: the long-standing condition. Med Oral Patol Oral Cir Bucal. 2016;21:e776\u201383. PMID:27694782","DOI":"10.4317\/medoral.21221"},{"key":"44","doi-asserted-by":"crossref","unstructured":"[44] Ziegler CM,Haag C,M\u00fchling J. Treatment of recurrent temporomandibular joint dislocation with intramuscular botulinum toxin injection. Clin Oral Investig. 2003;7:52\u20135. https:\/\/doi.org\/10.1007\/s00784-002-0187-y PMID:12673439","DOI":"10.1007\/s00784-002-0187-y"},{"key":"45","doi-asserted-by":"crossref","unstructured":"[45] Prechel U,Ottl P,Ahlers OM,Neff A. The treatment of temporomandibular joint dislocation: A systematic review. Dtsch Arztebl Int. 2018;115:59\u201364. https:\/\/doi.org\/10.3238\/arztebl.2018.0059 PMID:29439762","DOI":"10.3238\/arztebl.2018.0059"},{"key":"46","doi-asserted-by":"crossref","unstructured":"[46] Oztel M,Bilski WM,Bilski A. Botulinum toxin used to treat recurrent dislocation of the temporomandibular joint in a patient with osteoporosis. Br J Oral Maxillofac Surg. 2017;55:e1\u20132. https:\/\/doi.org\/10.1016\/j.bjoms.2016.05.012 PMID:27256802","DOI":"10.1016\/j.bjoms.2016.05.012"},{"key":"47","unstructured":"[47] Stark TR,Perez CV,Okeson JP. Recurrent TMJ dislocation managed with botulinum toxin type a injections in a pediatric patient. Pediatr Dent. 2015;37:65\u20139. PMID:25685976"},{"key":"48","doi-asserted-by":"crossref","unstructured":"[48] Delcanho R,Val M,Nardini L,Manfredini D. Botulinum toxin for treating temporomandibular disorders: what is the evidence? J Oral Facial Pain Headache. 2022;36:6\u201320. https:\/\/doi.org\/10.11607\/ofph.3023 PMID:35298571","DOI":"10.11607\/ofph.3023"},{"key":"49","doi-asserted-by":"crossref","unstructured":"[49] Chaudhry N,Srivastava A,Joshi L. Hemifacial spasm: the past, present and future. J Neurol Sci. 2015;356:27\u201331. https:\/\/doi.org\/10.1016\/j.jns.2015.06.032 PMID:26111430","DOI":"10.1016\/j.jns.2015.06.032"},{"key":"50","doi-asserted-by":"crossref","unstructured":"[50] Yaltho TC,Jankovic J. The many faces of hemifacial spasm: differential diagnosis of unilateral facial spasms. Mov Disord. 2011;26:1582\u201392. https:\/\/doi.org\/10.1002\/mds.23692 PMID:21469208","DOI":"10.1002\/mds.23692"},{"key":"51","doi-asserted-by":"crossref","unstructured":"[51] Defazio G,Abbruzzese G,Girlanda P,Vacca L,Curr\u00e0 A,De Salvia R,<i>et al.<\/i> Botulinum toxin A treatment for primary hemifacial spasm: a 10-year multicenter study. Arch Neurol. 2002;59:418\u201320. https:\/\/doi.org\/10.1001\/archneur.59.3.418 PMID:11890846","DOI":"10.1001\/archneur.59.3.418"},{"key":"52","doi-asserted-by":"crossref","unstructured":"[52] Costa J,Esp\u00edrito-Santo CC,Borges AA,Ferreira J,Coelho MM,Moore P,<i>et al.<\/i> Botulinum toxin type A therapy for hemifacial spasm. Cochrane Libr. 2005;2005:CD004899. https:\/\/doi.org\/10.1002\/14651858.CD004899.pub2 PMID:15674968","DOI":"10.1002\/14651858.CD004899.pub2"},{"key":"53","doi-asserted-by":"crossref","unstructured":"[53] Jost WH,Kohl A. Botulinum toxin: evidence-based medicine criteria in blepharospasm and hemifacial spasm. J Neurol. 2001;248(suppl 1):I21\u20134. https:\/\/doi.org\/10.1007\/PL00007813 PMID:11357234","DOI":"10.1007\/PL00007813"},{"key":"54","doi-asserted-by":"crossref","unstructured":"[54] Tambasco N,Filidei M,Nigro P,Parnetti L,Simoni S. Botulinum toxin for the treatment of hemifacial spasm: an update on clinical studies. Toxins (Basel). 2021;13:881. https:\/\/doi.org\/10.3390\/toxins13120881 PMID:34941718","DOI":"10.3390\/toxins13120881"},{"key":"55","unstructured":"[55] Raoofi S,Khorshidi H,Najafi M. Etiology, diagnosis and management of oromandibular dystonia: an update for stomatologists. J Dent (Shiraz). 2017;18:73\u201381. PMID:28620630"},{"key":"56","doi-asserted-by":"crossref","unstructured":"[56] Hallett M,Benecke R,Blitzer A,Comella CL. Treatment of focal dystonias with botulinum neurotoxin. Toxicon. 2009;54:628\u201333. https:\/\/doi.org\/10.1016\/j.toxicon.2008.12.008 PMID:19103214","DOI":"10.1016\/j.toxicon.2008.12.008"},{"key":"57","doi-asserted-by":"crossref","unstructured":"[57] Watt E,Sangani I,Crawford F,Gillgrass T. The role of a dentist in managing patients with dystonia. Dent Update. 2013;40:846\u20138. https:\/\/doi.org\/10.12968\/denu.2013.40.10.846 PMID:24597030","DOI":"10.12968\/denu.2013.40.10.846"},{"key":"58","unstructured":"[58] Thorburn DN,Lee KH. Oromandibular dystonia following dental treatment: case reports and discussion. N Z Dent J. 2009;105:18\u201321. PMID:19418679"},{"key":"59","doi-asserted-by":"crossref","unstructured":"[59] Yoshida K. Sensory trick splint as a multimodal therapy for oromandibular dystonia. J Prosthodont Res. 2018;62:239\u201344. https:\/\/doi.org\/10.1016\/j.jpor.2017.09.004 PMID:29126810","DOI":"10.1016\/j.jpor.2017.09.004"},{"key":"60","doi-asserted-by":"crossref","unstructured":"[60] Tan EK,Jankovic J. Botulinum toxin A in patients with oromandibular dystonia: long-term follow-up. Neurology. 1999;53:2102\u20137. https:\/\/doi.org\/10.1212\/WNL.53.9.2102 PMID:10599789","DOI":"10.1212\/WNL.53.9.2102"},{"key":"61","doi-asserted-by":"crossref","unstructured":"[61] Anandan C,Jankovic J. botulinum toxin in movement disorders: an update. Toxins (Basel). 2021;13:42. https:\/\/doi.org\/10.3390\/toxins13010042 PMID:33430071","DOI":"10.3390\/toxins13010042"},{"key":"62","doi-asserted-by":"crossref","unstructured":"[62] Maestre-Ferr\u00edn L,Burguera JA,Pe\u00f1arrocha-Diago M,Pe\u00f1arrocha-Diago M. Oromandibular dystonia: a dental approach. Med Oral Patol Oral Cir Bucal. 2010;15:e25\u20137. PMID:19680172","DOI":"10.4317\/medoral.15.e25"},{"key":"63","doi-asserted-by":"crossref","unstructured":"[63] Stew B,Williams H. Modern management of facial palsy: a review of current literature. Br J Gen Pract. 2013;63:109\u201310. https:\/\/doi.org\/10.3399\/bjgp13X663262 PMID:23561689","DOI":"10.3399\/bjgp13X663262"},{"key":"64","doi-asserted-by":"crossref","unstructured":"[64] House JW,Brackmann DE. Facial nerve grading system. Otolaryngol Head Neck Surg. 1985;93:146\u20137. https:\/\/doi.org\/10.1177\/019459988509300202 PMID:3921901","DOI":"10.1177\/019459988509300202"},{"key":"65","doi-asserted-by":"crossref","unstructured":"[65] Ross B,Fradet G,Nedzelski J. Development of a sensitive clinical facial grading system. Otolaryngol Head Neck Surg. 1996;114:380\u20136. https:\/\/doi.org\/10.1016\/S0194-5998(96)70206-1 PMID:8649870","DOI":"10.1016\/S0194-59989670206-1"},{"key":"66","doi-asserted-by":"crossref","unstructured":"[66] Maio M\u00b4. Use of botulinum toxin in facial paralysis. J Cosmet Laser Ther. 2003;5:216\u20137. https:\/\/doi.org\/10.1080\/14764170310021913 PMID:14741836","DOI":"10.1080\/14764170310021913"},{"key":"67","doi-asserted-by":"crossref","unstructured":"[67] Cabin JA,Massry GG,Azizzadeh B. Botulinum toxin in the management of facial paralysis. Curr Opin Otolaryngol Head Neck Surg. 2015;23:272\u201380. https:\/\/doi.org\/10.1097\/MOO.0000000000000176 PMID:26101876","DOI":"10.1097\/MOO.0000000000000176"},{"key":"68","doi-asserted-by":"crossref","unstructured":"[68] Mehdizadeh OB,Diels J,White WM. Botulinum toxin in the treatment of facial paralysis. Facial Plast Surg Clin North Am. 2016;24:11\u201320. https:\/\/doi.org\/10.1016\/j.fsc.2015.09.008 PMID:26611697","DOI":"10.1016\/j.fsc.2015.09.008"},{"key":"69","doi-asserted-by":"crossref","unstructured":"[69] de Sanctis Pecora C,Shitara D. Botulinum toxin type a to improve facial symmetry in facial palsy: a practical guideline and clinical experience. Toxins (Basel). 2021;13:159. https:\/\/doi.org\/10.3390\/toxins13020159 PMID:33670477","DOI":"10.3390\/toxins13020159"},{"key":"70","doi-asserted-by":"crossref","unstructured":"[70] Husseman J,Mehta R. Management of Synkinesis. Facial Plast Surg. 2008;24:242\u20139. https:\/\/doi.org\/10.1055\/s-2008-1075840 PMID:18470836","DOI":"10.1055\/s-2008-1075840"},{"key":"71","unstructured":"[71] Mandrini S,Comelli M,Dall\u2019angelo A,Togni R,Cecini M,Pavese C,<i>et al.<\/i> Long-term facial improvement after repeated BoNT-A injections and mirror biofeedback exercises for chronic facial synkinesis: a case-series study. Eur J Phys Rehabil Med. 2016;52:810\u20138. PMID:27164539"},{"key":"72","doi-asserted-by":"crossref","unstructured":"[72] Azuma T,Nakamura K,Takahashi M,Ohyama S,Toda N,Iwasaki H,<i>et al.<\/i> Mirror biofeedback rehabilitation after administration of single-dose botulinum toxin for treatment of facial synkinesis. Otolaryngol Head Neck Surg. 2012;146:40\u20135. https:\/\/doi.org\/10.1177\/0194599811424125 PMID:21965443","DOI":"10.1177\/0194599811424125"},{"key":"73","doi-asserted-by":"crossref","unstructured":"[73] Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders. Cephalalgia. 2018;38:1\u2013211.","DOI":"10.1177\/0333102417738202"},{"key":"74","doi-asserted-by":"crossref","unstructured":"[74] Mungoven TJ,Henderson LA,Meylakh N. Chronic migraine pathophysiology and treatment: a review of current perspectives. Front Pain Res. 2021;2:705276. https:\/\/doi.org\/10.3389\/fpain.2021.705276 PMID:35295486","DOI":"10.3389\/fpain.2021.705276"},{"key":"75","doi-asserted-by":"crossref","unstructured":"[75] Becker WJ. Botulinum toxin in the treatment of headache. Toxins (Basel). 2020;12:803. https:\/\/doi.org\/10.3390\/toxins12120803 PMID:33348571","DOI":"10.3390\/toxins12120803"},{"key":"76","doi-asserted-by":"crossref","unstructured":"[76] Bruloy E,Sinna R,Grolleau JL,Bout-Roumazeilles A,Berard E,Chaput B. Botulinum toxin versus placebo: a meta-analysis of prophylactic treatment for migraine. Plast Reconstr Surg. 2019;143:239\u201350. https:\/\/doi.org\/10.1097\/PRS.0000000000005111 PMID:30589800","DOI":"10.1097\/PRS.0000000000005111"},{"key":"77","doi-asserted-by":"crossref","unstructured":"[77] Negro A,Curto M,Lionetto L,Martelletti P. A two years open-label prospective study of OnabotulinumtoxinA 195 U in medication overuse headache: a real-world experience. J Headache Pain. 2015;17:1. https:\/\/doi.org\/10.1186\/s10194-016-0591-3 PMID:26792662","DOI":"10.1186\/s10194-016-0591-3"},{"key":"78","doi-asserted-by":"crossref","unstructured":"[78] Ailani J,Burch RC,Robbins MS; Board of Directors of the American Headache Society. The American Headache Society Consensus Statement: update on integrating new migraine treatments into clinical practice. Headache. 2021;61:1021\u201339. https:\/\/doi.org\/10.1111\/head.14153 PMID:34160823","DOI":"10.1111\/head.14153"},{"key":"79","doi-asserted-by":"crossref","unstructured":"[79] Pellesi L,Do TP,Ashina H,Ashina M,Burstein R. Dual therapy with anti-CGRP monoclonal antibodies and botulinum toxin for migraine prevention: is there a rationale? Headache. 2020;60:1056\u201365. https:\/\/doi.org\/10.1111\/head.13843 PMID:32437038","DOI":"10.1111\/head.13843"},{"key":"80","doi-asserted-by":"crossref","unstructured":"[80] Armanious M,Khalil N,Lu Y,Jimenez-Sanders R. Erenumab and onabotulinumtoxina combination therapy for the prevention of intractable chronic migraine without aura: a retrospective analysis. J Pain Palliat Care Pharmacother. 2021;35:1\u20136. https:\/\/doi.org\/10.1080\/15360288.2020.1829249 PMID:33125303","DOI":"10.1080\/15360288.2020.1829249"},{"key":"81","doi-asserted-by":"crossref","unstructured":"[81] Gambeta E,Chichorro JG,Zamponi GW. Trigeminal neuralgia: an overview from pathophysiology to pharmacological treatments. Mol Pain. 2020;16. https:\/\/doi.org\/10.1177\/1744806920901890 PMID:31908187","DOI":"10.1177\/1744806920901890"},{"key":"82","doi-asserted-by":"crossref","unstructured":"[82] Cruccu G,Gronseth G,Alksne J,Argoff C,Brainin M,Burchiel K,<i>et al.<\/i>; American Academy of Neurology Society; European Federation of Neurological Society. AAN-EFNS guidelines on trigeminal neuralgia management. Eur J Neurol. 2008;15:1013\u201328. https:\/\/doi.org\/10.1111\/j.1468-1331.2008.02185.x PMID:18721143","DOI":"10.1111\/j.1468-1331.2008.02185.x"},{"key":"83","doi-asserted-by":"crossref","unstructured":"[83] Piovesan EJ,Teive HG,Kowacs PA,Coletta MVD,Werneck LC,Silberstein SD. An open study of botulinum-A toxin treatment of trigeminal neuralgia. Neurology. 2005;65:1306\u20138. https:\/\/doi.org\/10.1212\/01.wnl.0000180940.98815.74 PMID:16247065","DOI":"10.1212\/01.wnl.0000180940.98815.74"},{"key":"84","doi-asserted-by":"crossref","unstructured":"[84] Allam N,Brasil-Neto JP,Brown G,Tomaz C. Injections of botulinum toxin type a produce pain alleviation in intractable trigeminal neuralgia. Clin J Pain. 2005;21:182\u20134. https:\/\/doi.org\/10.1097\/00002508-200503000-00010 PMID:15722812","DOI":"10.1097\/00002508-200503000-00010"},{"key":"85","doi-asserted-by":"crossref","unstructured":"[85] Wu S,Lian Y,Zhang H,Chen Y,Wu C,Li S,<i>et al.<\/i> Botulinum Toxin Type A for refractory trigeminal neuralgia in older patients: a better therapeutic effect. J Pain Res. 2019;12:2177\u201386. https:\/\/doi.org\/10.2147\/JPR.S205467 PMID:31410051","DOI":"10.2147\/JPR.S205467"},{"key":"86","doi-asserted-by":"crossref","unstructured":"[86] Bohluli B,Motamedi MHK,Bagheri SC,Bayat M,Lassemi E,Navi F,<i>et al.<\/i> Use of botulinum toxin A for drug-refractory trigeminal neuralgia: preliminary report. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2011;111:47\u201350. https:\/\/doi.org\/10.1016\/j.tripleo.2010.04.043 PMID:20674409","DOI":"10.1016\/j.tripleo.2010.04.043"},{"key":"87","doi-asserted-by":"crossref","unstructured":"[87] Wu CJ,Lian YJ,Zheng YK,Zhang HF,Chen Y,Xie NC,<i>et al.<\/i> Botulinum toxin type A for the treatment of trigeminal neuralgia: results from a randomized, double-blind, placebo-controlled trial. Cephalalgia. 2012;32:443\u201350. https:\/\/doi.org\/10.1177\/0333102412441721 PMID:22492424","DOI":"10.1177\/0333102412441721"},{"key":"88","doi-asserted-by":"crossref","unstructured":"[88] Lunde HMB,Torkildsen \u00d8,B\u00f8 L,Bertelsen AK. Botulinum toxin as monotherapy in symptomatic trigeminal neuralgia. Headache. 2016;56:1035\u20139. https:\/\/doi.org\/10.1111\/head.12791 PMID:26992044","DOI":"10.1111\/head.12791"},{"key":"89","doi-asserted-by":"crossref","unstructured":"[89] Kumada A,Matsuka Y,Spigelman I,Maruhama K,Yamamoto Y,Neubert JK,<i>et al.<\/i> Intradermal injection of Botulinum toxin type A alleviates infraorbital nerve constriction-induced thermal hyperalgesia in an operant assay. J Oral Rehabil. 2012;39:63\u201372. https:\/\/doi.org\/10.1111\/j.1365-2842.2011.02236.x PMID:21793870","DOI":"10.1111\/j.1365-2842.2011.02236.x"},{"key":"90","doi-asserted-by":"crossref","unstructured":"[90] Kitamura Y,Matsuka Y,Spigelman I,Ishihara Y,Yamamoto Y,Sonoyama W,<i>et al.<\/i> Botulinum toxin type a (150 kDa) decreases exaggerated neurotransmitter release from trigeminal ganglion neurons and relieves neuropathy behaviors induced by infraorbital nerve constriction. Neuroscience. 2009;159:1422\u20139. https:\/\/doi.org\/10.1016\/j.neuroscience.2009.01.066 PMID:19409226","DOI":"10.1016\/j.neuroscience.2009.01.066"},{"key":"91","doi-asserted-by":"crossref","unstructured":"[91] Waskitho A,Yamamoto Y,Raman S,Kano F,Yan H,Raju R,<i>et al.<\/i> Peripherally administered botulinum toxin type A localizes bilaterally in trigeminal ganglia of animal model. Toxins (Basel). 2021;13:704. https:\/\/doi.org\/10.3390\/toxins13100704 PMID:34678997","DOI":"10.3390\/toxins13100704"},{"key":"92","doi-asserted-by":"crossref","unstructured":"[92] Garnock-Jones KP. Glycopyrrolate oral solution: for chronic, severe drooling in pediatric patients with neurologic conditions. Paediatr Drugs. 2012;14:263\u20139. https:\/\/doi.org\/10.2165\/11208120-000000000-00000 PMID:22646067","DOI":"10.2165\/11208120-000000000-00000"},{"key":"93","doi-asserted-by":"crossref","unstructured":"[93] Lakraj A,Moghimi N,Jabbari B. Sialorrhea: anatomy, pathophysiology and treatment with emphasis on the role of botulinum toxins. Toxins (Basel). 2013;5:1010\u201331. https:\/\/doi.org\/10.3390\/toxins5051010 PMID:23698357","DOI":"10.3390\/toxins5051010"},{"key":"94","unstructured":"[94] Hockstein NG,Samadi DS,Gendron K,Handler SD. Sialorrhea: a management challenge. Am Fam Physician. 2004;69:2628\u201334. PMID:15202698"},{"key":"95","doi-asserted-by":"crossref","unstructured":"[95] Jongerius PH,Hoogen FJA,Limbeek J,Gabre\u00ebls FJ,Hulst K,Rotteveel JJ. Effect of botulinum toxin in the treatment of drooling: a controlled clinical trial. Pediatrics. 2004;114:620\u20137. https:\/\/doi.org\/10.1542\/peds.2003-1104-L PMID:15342830","DOI":"10.1542\/peds.2003-1104-L"},{"key":"96","doi-asserted-by":"crossref","unstructured":"[96] Suskind DL,Tilton A. Clinical study of botulinum-A toxin in the treatment of sialorrhea in children with cerebral palsy. Laryngoscope. 2002;112:73\u201381. https:\/\/doi.org\/10.1097\/00005537-200201000-00014 PMID:11802042","DOI":"10.1097\/00005537-200201000-00014"},{"key":"97","doi-asserted-by":"crossref","unstructured":"[97] Mantelakis A,Lafford G,Lee CW,Spencer H,Deval JL,Joshi A. Frey\u2019s syndrome: a review of aetiology and treatment. Cureus. 2021;13:e20107. https:\/\/doi.org\/10.7759\/cureus.20107 PMID:34873562","DOI":"10.7759\/cureus.20107"},{"key":"98","doi-asserted-by":"crossref","unstructured":"[98] de Bree R,van der Waal I,Leemans CR. Management of frey syndrome. Head Neck. 2007;29:773\u20138. https:\/\/doi.org\/10.1002\/hed.20568 PMID:17230557","DOI":"10.1002\/hed.20568"},{"key":"99","doi-asserted-by":"crossref","unstructured":"[99] Xie S,Wang K,Xu T,Guo XS,Shan XF,Cai ZG. Efficacy and safety of botulinum toxin type A for treatment of Frey\u2019s syndrome: evidence from 22 published articles. Cancer Med. 2015;4:1639\u201350. https:\/\/doi.org\/10.1002\/cam4.504 PMID:26310612","DOI":"10.1002\/cam4.504"},{"key":"100","doi-asserted-by":"crossref","unstructured":"[100] Jansen S,Jerowski M,Ludwig L,Fischer-Krall E,Beutner D,Grosheva M. Botulinum toxin therapy in Frey\u2019s syndrome: a retrospective study of 440 treatments in 100 patients. Clin Otolaryngol. 2017;42:295\u2013300. https:\/\/doi.org\/10.1111\/coa.12719 PMID:27513469","DOI":"10.1111\/coa.12719"},{"key":"101","doi-asserted-by":"crossref","unstructured":"[101] Mostafa D. A successful management of sever gummy smile using gingivectomy and botulinum toxin injection: A case report. Int J Surg Case Rep. 2018;42:169\u201374. https:\/\/doi.org\/10.1016\/j.ijscr.2017.11.055 PMID:29248835","DOI":"10.1016\/j.ijscr.2017.11.055"},{"key":"102","doi-asserted-by":"crossref","unstructured":"[102] Jananni M,Sivaramakrishnan M,Libby T. Surgical correction of excessive gingival display in class I vertical maxillary excess: mucosal strip technique. J Nat Sci Biol Med. 2014;5:494\u20138. https:\/\/doi.org\/10.4103\/0976-9668.136290 PMID:25097447","DOI":"10.4103\/0976-9668.136290"},{"key":"103","unstructured":"[103] Rosenblatt A,Simon Z. Lip repositioning for reduction of excessive gingival display: a clinical report. Int J Periodontics Restorative Dent. 2006;26:433\u20137. PMID:17073353"},{"key":"104","doi-asserted-by":"crossref","unstructured":"[104] Polo M. Botulinum toxin type A in the treatment of excessive gingival display. Am J Orthod Dentofacial Orthop. 2005;127:214\u20138. https:\/\/doi.org\/10.1016\/j.ajodo.2004.09.013 PMID:15750541","DOI":"10.1016\/j.ajodo.2004.09.013"},{"key":"105","doi-asserted-by":"crossref","unstructured":"[105] Mazzuco R,Hexsel D. Gummy smile and botulinum toxin: A new approach based on the gingival exposure area. J Am Acad Dermatol. 2010;63:1042\u201351. https:\/\/doi.org\/10.1016\/j.jaad.2010.02.053 PMID:21093661","DOI":"10.1016\/j.jaad.2010.02.053"},{"key":"106","doi-asserted-by":"crossref","unstructured":"[106] Jaspers GWC,Pijpe J,Jansma J. The use of botulinum toxin type A in cosmetic facial procedures. Int J Oral Maxillofac Surg. 2011;40:127\u201333. https:\/\/doi.org\/10.1016\/j.ijom.2010.09.014 PMID:20965695","DOI":"10.1016\/j.ijom.2010.09.014"},{"key":"107","doi-asserted-by":"crossref","unstructured":"[107] Benedetto A. Asymmetrical smiles corrected by botulinum toxin serotype A. Dermatol Surg. 2007;33:S32\u20136. https:\/\/doi.org\/10.1111\/j.1524-4725.2006.32329.x PMID:17241412","DOI":"10.1111\/j.1524-4725.2006.32329.x"},{"key":"108","doi-asserted-by":"crossref","unstructured":"[108] Heydenrych I. The treatment of facial asymmetry with botulinum toxin: current concepts, guidelines, and future trends. Indian J Plast Surg. 2020;53:219\u201329. https:\/\/doi.org\/10.1055\/s-0040-1715189 PMID:32884188","DOI":"10.1055\/s-0040-1715189"},{"key":"109","doi-asserted-by":"crossref","unstructured":"[109] Choi YJ,Kim JS,Gil YC,Phetudom T,Kim HJ,Tansatit T,<i>et al.<\/i> Anatomical considerations regarding the location and boundary of the depressor anguli oris muscle with reference to botulinum toxin injection. Plast Reconstr Surg. 2014;134:917\u201321. https:\/\/doi.org\/10.1097\/PRS.0000000000000589 PMID:25347627","DOI":"10.1097\/PRS.0000000000000589"},{"key":"110","doi-asserted-by":"crossref","unstructured":"[110] Lelouarn C,Buis J,Buthiau D. Treatment of depressor anguli oris weakening with the face recurve concept. Aesthet Surg J. 2006;26:603\u201311. https:\/\/doi.org\/10.1016\/j.asj.2006.08.001 PMID:19338950","DOI":"10.1016\/j.asj.2006.08.001"},{"key":"111","doi-asserted-by":"crossref","unstructured":"[111] Goldman A,Wollina U. Elevation of the corner of the mouth using Botulinum toxin type A. J Cutan Aesthet Surg. 2010;3:145\u201350. https:\/\/doi.org\/10.4103\/0974-2077.74490 PMID:21430826","DOI":"10.4103\/0974-2077.74490"},{"key":"112","doi-asserted-by":"crossref","unstructured":"[112] Hur MS,Hu KS,Cho JY,Kwak HH,Song WC,Koh KS,<i>et al.<\/i> Topography and location of the depressor anguli oris muscle with a reference to the mental foramen. Surg Radiol Anat. 2008;30:403\u20137. https:\/\/doi.org\/10.1007\/s00276-008-0343-4 PMID:18385924","DOI":"10.1007\/s00276-008-0343-4"},{"key":"113","doi-asserted-by":"crossref","unstructured":"[113] Perkins SW. The corner of the mouth lift and management of the oral commissure grooves. Facial Plast Surg Clin North Am. 2007;15:471\u20136, vii. https:\/\/doi.org\/10.1016\/j.fsc.2007.08.005 PMID:18005887","DOI":"10.1016\/j.fsc.2007.08.005"},{"key":"114","doi-asserted-by":"crossref","unstructured":"[114] Starobova H,Vetter I. Pathophysiology of chemotherapy-induced peripheral neuropathy. Front Mol Neurosci. 2017;10:174. https:\/\/doi.org\/10.3389\/fnmol.2017.00174 PMID:28620280","DOI":"10.3389\/fnmol.2017.00174"},{"key":"115","doi-asserted-by":"crossref","unstructured":"[115] Niamtu J III. Aesthetic uses of botulinum toxin a. J Oral Maxillofac Surg. 1999;57:1228\u201333. https:\/\/doi.org\/10.1016\/S0278-2391(99)90493-7 PMID:10513870","DOI":"10.1016\/S0278-2391(99)90493-7"},{"key":"116","doi-asserted-by":"crossref","unstructured":"[116] Srivastava S, Kharbanda S, Pal US, Shah V. Applications of botulinum toxin in dentistry: A comprehensive review. Natl J Maxillofac Surg. 2015;6:152\u20139. https:\/\/doi.org\/10.4103\/0975-5950.183860 PMID:27390488","DOI":"10.4103\/0975-5950.183860"},{"key":"117","doi-asserted-by":"crossref","unstructured":"[117] Niamtu J III. Botulinum toxin A: A review of 1,085 oral and maxillofacial patient treatments. J Oral Maxillofac Surg. 2003;61:317\u201324. https:\/\/doi.org\/10.1053\/joms.2003.50069 PMID:12618971","DOI":"10.1053\/joms.2003.50069"},{"key":"118","doi-asserted-by":"crossref","unstructured":"[118] Frampton JE,Easthope SE. Botulinum toxin A (Botox Cosmetic): a review of its use in the treatment of glabellar frown lines. Am J Clin Dermatol. 2003;4:709\u201325. https:\/\/doi.org\/10.2165\/00128071-200304100-00005 PMID:14507232","DOI":"10.2165\/00128071-200304100-00005"},{"key":"119","doi-asserted-by":"crossref","unstructured":"[119] Matarasso A,Matarasso SL,Brandt FS,Bellman B. Botulinum A exotoxin for the management of platysma bands. Plast Reconstr Surg. 1999;103:645\u201352. https:\/\/doi.org\/10.1097\/00006534-199902000-00043 PMID:9950556","DOI":"10.1097\/00006534-199902000-00043"},{"key":"120","doi-asserted-by":"crossref","unstructured":"[120] Seitz CM,Strack RW,Wyrick DL. Cigarette smoking and facial wrinkles: a review of the literature. J Smok Cessat. 2012;7:18\u201324. https:\/\/doi.org\/10.1017\/jsc.2012.8","DOI":"10.1017\/jsc.2012.8"},{"key":"121","doi-asserted-by":"crossref","unstructured":"[121] Semchyshyn N,Sengelmann RD. Botulinum toxin A treatment of perioral rhytides. Dermatol Surg. 2003;29:490\u20135. PMID:12752516","DOI":"10.1046\/j.1524-4725.2003.29118.x"},{"key":"122","unstructured":"[122] Kebede B,Megersa S. Idiopathic masseter muscle hypertrophy. Ethiop J Health Sci. 2011;21:209\u201312. PMID:22435002"},{"key":"123","doi-asserted-by":"crossref","unstructured":"[123] Baek RM,Han SB,Baek SM. Surgical correction of the face with the square jaw and weak chin: angle-to-chin bone transfer. Plast Reconstr Surg. 2001;108:225\u201331. https:\/\/doi.org\/10.1097\/00006534-200107000-00036 PMID:11420528","DOI":"10.1097\/00006534-200107000-00036"},{"key":"124","doi-asserted-by":"crossref","unstructured":"[124] Ham JW. Masseter muscle reduction procedure with radiofrequency coagulation. J Oral Maxillofac Surg. 2009;67:457\u201363. https:\/\/doi.org\/10.1016\/j.joms.2006.04.012 PMID:19138629","DOI":"10.1016\/j.joms.2006.04.012"},{"key":"125","doi-asserted-by":"crossref","unstructured":"[125] Chang CS,Kang GCW. Achieving ideal lower face aesthetic contours: combination of tridimensional fat grafting to the chin with masseter botulinum toxin injection. Aesthet Surg J. 2016;36:1093\u2013100. https:\/\/doi.org\/10.1093\/asj\/sjw082 PMID:27193172","DOI":"10.1093\/asj\/sjw082"},{"key":"126","doi-asserted-by":"crossref","unstructured":"[126] Yu CC,Chen PKT,Chen YR. Botulinum toxin a for lower facial contouring: a prospective study. Aesthetic Plast Surg. 2007;31:445\u201351. https:\/\/doi.org\/10.1007\/s00266-007-0081-8 PMID:17674088","DOI":"10.1007\/s00266-007-0081-8"},{"key":"127","doi-asserted-by":"crossref","unstructured":"[127] To EW, Ahuja AT, Ho WS, King WW, Wong WK, Pang PC,<i>et al.<\/i> A prospective study of the effect of botulinum toxin A on masseteric muscle hypertrophy with ultrasonographic and electromyographic measurement. Br J Plast Surg. 2001;54:197\u2013200. https:\/\/doi.org\/10.1054\/bjps.2000.3526 PMID:11254408","DOI":"10.1054\/bjps.2000.3526"},{"key":"128","doi-asserted-by":"crossref","unstructured":"[128] De Carli BMG,Magro AKD,Souza-Silva BN,Matos FS,De Carli JP,Paranhos LR,<i>et al.<\/i> The effect of laser and botulinum toxin in the treatment of myofascial pain and mouth opening: A randomized clinical trial. J Photochem Photobiol B. 2016;159:120\u20133. https:\/\/doi.org\/10.1016\/j.jphotobiol.2016.03.038 PMID:27045280","DOI":"10.1016\/j.jphotobiol.2016.03.038"},{"key":"129","doi-asserted-by":"crossref","unstructured":"[129] Fu KY,Chen HM,Sun ZP,Zhang ZK,Ma XC. Long-term efficacy of botulinum toxin type A for the treatment of habitual dislocation of the temporomandibular joint. Br J Oral Maxillofac Surg. 2010;48:281\u20134. https:\/\/doi.org\/10.1016\/j.bjoms.2009.07.014 PMID:19665263","DOI":"10.1016\/j.bjoms.2009.07.014"},{"key":"130","doi-asserted-by":"crossref","unstructured":"[130] Li YJ,Huang Y,Ding Q,Gu ZH,Pan XL. Evaluation of concentrations of botulinum toxin A for the treatment of hemifacial spasm: a randomized double-blind crossover trial. Genet Mol Res. 2015;14:1136\u201344. https:\/\/doi.org\/10.4238\/2015.February.6.17 PMID:25730053","DOI":"10.4238\/2015.February.6.17"},{"key":"131","doi-asserted-by":"crossref","unstructured":"[131] Lolekha P,Choolam A,Kulkantrakorn K. A comparative crossover study on the treatment of hemifacial spasm and blepharospasm: preseptal and pretarsal botulinum toxin injection techniques. Neurol Sci. 2017;38:2031\u20136. https:\/\/doi.org\/10.1007\/s10072-017-3107-2 PMID:28884242","DOI":"10.1007\/s10072-017-3107-2"},{"key":"132","doi-asserted-by":"crossref","unstructured":"[132] Bentivoglio AR,Ialongo T,Bove F,De Nigris F,Fasano A. Retrospective evaluation of the dose equivalence of Botox\u00ae and Dysport\u00ae in the management of blepharospasm and hemifacial spasm: a novel paradigm for a never ending story. Neurol Sci. 2012;33:261\u20137. https:\/\/doi.org\/10.1007\/s10072-011-0672-7 PMID:21710123","DOI":"10.1007\/s10072-011-0672-7"},{"key":"133","doi-asserted-by":"crossref","unstructured":"[133] Ababneh OH,Cetinkaya A,Kulwin DR. Long-term efficacy and safety of botulinum toxin A injections to treat blepharospasm and hemifacial spasm. Clin Exp Ophthalmol. 2014;42:254\u201361. https:\/\/doi.org\/10.1111\/ceo.12165 PMID:23844601","DOI":"10.1111\/ceo.12165"},{"key":"134","doi-asserted-by":"crossref","unstructured":"[134] Hallett M,Albanese A,Dressler D,Segal KR,Simpson DM,Truong D,<i>et al.<\/i> Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders. Toxicon. 2013;67:94\u2013114. https:\/\/doi.org\/10.1016\/j.toxicon.2012.12.004 PMID:23380701","DOI":"10.1016\/j.toxicon.2012.12.004"},{"key":"135","doi-asserted-by":"crossref","unstructured":"[135] Yoshimura DM,Aminoff MJ,Tami TA,Scott AB. Treatment of hemifacial spasm with botulinum toxin. Muscle Nerve. 1992;15:1045\u20139. https:\/\/doi.org\/10.1002\/mus.880150909 PMID:1518513","DOI":"10.1002\/mus.880150909"},{"key":"136","doi-asserted-by":"crossref","unstructured":"[136] Ruiz-de-Le\u00f3n-Hern\u00e1ndez G,D\u00edaz-S\u00e1nchez RM,Torres-Lagares D,Hern\u00e1ndez-Pacheco E,Gonz\u00e1lez-Mart\u00edn M,Serrera-Figallo MA. Botulinum toxin A for patients with orofacial dystonia: prospective, observational, single-centre study. Int J Oral Maxillofac Surg. 2018;47:386\u201391. https:\/\/doi.org\/10.1016\/j.ijom.2017.11.006 PMID:29208327","DOI":"10.1016\/j.ijom.2017.11.006"},{"key":"137","doi-asserted-by":"crossref","unstructured":"[137] Giorni A,Coyne T,Silburn PA,Mellick GD,Sah P,Windels F. Changes in pallidal neural activity following long-term symptom improvement from botulinum toxin treatment in DYT6 dystonia: a case report. J Med Case Reports. 2022;16:15. https:\/\/doi.org\/10.1186\/s13256-021-03215-4 PMID:34998426","DOI":"10.1186\/s13256-021-03215-4"},{"key":"138","doi-asserted-by":"crossref","unstructured":"[138] M\u00f8ller E,Werdelin LM,Bakke M,Dalager T,Prytz S,Regeur L. Treatment of perioral dystonia with botulinum toxin in 4 cases of Meige\u2019s syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2003;96:544\u20139. https:\/\/doi.org\/10.1016\/j.tripleo.2003.08.011 PMID:14600688","DOI":"10.1016\/j.tripleo.2003.08.011"},{"key":"139","doi-asserted-by":"crossref","unstructured":"[139] Filipo R,Spahiu I,Covelli E,Nicastri M,Bertoli GA. Botulinum toxin in the treatment of facial synkinesis and hyperkinesis. Laryngoscope. 2012;122:266\u201370. https:\/\/doi.org\/10.1002\/lary.22404 PMID:22252570","DOI":"10.1002\/lary.22404"},{"key":"140","doi-asserted-by":"crossref","unstructured":"[140] Sundaram H,Signorini M,Liew S,Trindade de Almeida AR,Wu Y,Vieira Braz A,<i>et al.<\/i>; Global Aesthetics Consensus Group. Global aesthetics consensus: botulinum toxin type A-evidence based review, emerging concepts, and consensus recommendations for aesthetic use, including updates on complications. Plast Reconstr Surg. 2016;137:518e\u201329e. https:\/\/doi.org\/10.1097\/01.prs.0000475758.63709.23 PMID:26910696","DOI":"10.1097\/01.prs.0000475758.63709.23"},{"key":"141","doi-asserted-by":"crossref","unstructured":"[141] Maria CM,Kim J. Individualized management of facial synkinesis based on facial function. Acta Otolaryngol. 2017;137:1010\u20135. https:\/\/doi.org\/10.1080\/00016489.2017.1316871 PMID:28471705","DOI":"10.1080\/00016489.2017.1316871"},{"key":"142","doi-asserted-by":"crossref","unstructured":"[142] Welch MJ,Purkiss JR,Foster KA. Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon. 2000;38:245\u201358. https:\/\/doi.org\/10.1016\/S0041-0101(99)00153-1 PMID:10665805","DOI":"10.1016\/S0041-0101(99)00153-1"},{"key":"143","doi-asserted-by":"crossref","unstructured":"[143] Durham PL,Cady R,Cady R. Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy. Headache. 2004;44:35\u201343. https:\/\/doi.org\/10.1111\/j.1526-4610.2004.04007.x PMID:14979881","DOI":"10.1111\/j.1526-4610.2004.04007.x"},{"key":"144","doi-asserted-by":"crossref","unstructured":"[144] Burstein R,Blumenfeld AM,Silberstein SD,Manack Adams A,Brin MF. Mechanism of action of onabotulinumtoxinA in chronic migraine: a narrative review. Headache. 2020;60:1259\u201372. https:\/\/doi.org\/10.1111\/head.13849 PMID:32602955","DOI":"10.1111\/head.13849"},{"key":"145","doi-asserted-by":"crossref","unstructured":"[145] Aurora SK,Dodick DW,Turkel CC,DeGryse RE,Silberstein SD,Lipton RB,<i>et al.<\/i>; PREEMPT 1 Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia. 2010;30:793\u2013803. https:\/\/doi.org\/10.1177\/0333102410364676 PMID:20647170","DOI":"10.1177\/0333102410364676"},{"key":"146","doi-asserted-by":"crossref","unstructured":"[146] Diener HC,Dodick DW,Aurora SK,Turkel CC,DeGryse RE,Lipton RB,<i>et al.<\/i>; PREEMPT 2 Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia. 2010;30:804\u201314. https:\/\/doi.org\/10.1177\/0333102410364677 PMID:20647171","DOI":"10.1177\/0333102410364677"},{"key":"147","doi-asserted-by":"crossref","unstructured":"[147] Blumenfeld A,Silberstein SD,Dodick DW,Aurora SK,Turkel CC,Binder WJ. Method of injection of onabotulinumtoxinA for chronic migraine: a safe, well-tolerated, and effective treatment paradigm based on the PREEMPT clinical program. Headache. 2010;50:1406\u201318. https:\/\/doi.org\/10.1111\/j.1526-4610.2010.01766.x PMID:20958294","DOI":"10.1111\/j.1526-4610.2010.01766.x"},{"key":"148","doi-asserted-by":"crossref","unstructured":"[148] Ramachandran R,Lam C,Yaksh TL. Botulinum toxin in migraine: role of transport in trigemino-somatic and trigemino-vascular afferents. Neurobiol Dis. 2015;79:111\u201322. https:\/\/doi.org\/10.1016\/j.nbd.2015.04.011 PMID:25958249","DOI":"10.1016\/j.nbd.2015.04.011"},{"key":"149","doi-asserted-by":"crossref","unstructured":"[149] Egeo G,Fofi L,Barbanti P. Botulinum neurotoxin for the treatment of neuropathic pain. Front Neurol. 2020;11:716. https:\/\/doi.org\/10.3389\/fneur.2020.00716 PMID:32849195","DOI":"10.3389\/fneur.2020.00716"},{"key":"150","doi-asserted-by":"crossref","unstructured":"[150] Ngeow WC,Nair R. Injection of botulinum toxin type A (BOTOX) into trigger zone of trigeminal neuralgia as a means to control pain. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010;109:e47\u201350. https:\/\/doi.org\/10.1016\/j.tripleo.2009.03.021 PMID:20219585","DOI":"10.1016\/j.tripleo.2009.03.021"},{"key":"151","doi-asserted-by":"crossref","unstructured":"[151] Z\u00fa\u00f1iga C,Piedimonte F,D\u00edaz S,Micheli F. Acute treatment of trigeminal neuralgia with onabotulinum toxin A. Clin Neuropharmacol. 2013;36:146\u201350. https:\/\/doi.org\/10.1097\/WNF.0b013e31829cb60e PMID:24045604","DOI":"10.1097\/WNF.0b013e31829cb60e"},{"key":"152","doi-asserted-by":"crossref","unstructured":"[152] Shehata HS,El-Tamawy MS,Shalaby NM,Ramzy G. Botulinum toxin-type A: could it be an effective treatment option in intractable trigeminal neuralgia? J Headache Pain. 2013;14:92. https:\/\/doi.org\/10.1186\/1129-2377-14-92 PMID:24251833","DOI":"10.1186\/1129-2377-14-92"},{"key":"153","doi-asserted-by":"crossref","unstructured":"[153] Zhang H,Lian Y,Ma Y,Chen Y,He C,Xie N,<i>et al.<\/i> Two doses of botulinum toxin type A for the treatment of trigeminal neuralgia: observation of therapeutic effect from a randomized, double-blind, placebo-controlled trial. J Headache Pain. 2014;15:65. https:\/\/doi.org\/10.1186\/1129-2377-15-65 PMID:25263254","DOI":"10.1186\/1129-2377-15-65"},{"key":"154","doi-asserted-by":"crossref","unstructured":"[154] Hill F,Miller N,Walsh RA,Mockler D,McDowell R,Walshe M. Botulinum toxin for drooling in Parkinson\u2019s disease. Cochrane Libr. 2016;2016:CD012408. https:\/\/doi.org\/10.1002\/14651858.CD012408","DOI":"10.1002\/14651858.CD012408"},{"key":"155","doi-asserted-by":"crossref","unstructured":"[155] Srivanitchapoom P,Pandey S,Hallett M. Drooling in Parkinson\u2019s disease: A review. Parkinsonism Relat Disord. 2014;20:1109\u201318. https:\/\/doi.org\/10.1016\/j.parkreldis.2014.08.013 PMID:25200111","DOI":"10.1016\/j.parkreldis.2014.08.013"},{"key":"156","doi-asserted-by":"crossref","unstructured":"[156] Chou KL,Evatt M,Hinson V,Kompoliti K. Sialorrhea in Parkinson\u2019s disease: A review. Mov Disord. 2007;22:2306\u201313. https:\/\/doi.org\/10.1002\/mds.21646 PMID:17659637","DOI":"10.1002\/mds.21646"},{"key":"157","doi-asserted-by":"crossref","unstructured":"[157] Jongerius PH,Rotteveel JJ,van Limbeek J,Gabre\u00ebls FJM,van Hulst K,van den Hoogen FJA. Botulinum toxin effect on salivary flow rate in children with cerebral palsy. Neurology. 2004;63:1371\u20135. https:\/\/doi.org\/10.1212\/01.WNL.0000142040.57474.A6 PMID:15505151","DOI":"10.1212\/01.WNL.0000142040.57474.A6"},{"key":"158","doi-asserted-by":"crossref","unstructured":"[158] Bothwell JE,Clarke K,Dooley JM,Gordon KE,Anderson R,Wood EP,<i>et al.<\/i> Botulinum toxin A as a treatment for excessive drooling in children. Pediatr Neurol. 2002;27:18\u201322. https:\/\/doi.org\/10.1016\/S0887-8994(02)00381-8 PMID:12160968","DOI":"10.1016\/S0887-8994(02)00381-8"},{"key":"159","doi-asserted-by":"crossref","unstructured":"[159] Savarese R,Diamond M,Elovic E,Millis SR. Intraparotid injection of botulinum toxin A as a treatment to control sialorrhea in children with cerebral palsy. Am J Phys Med Rehabil. 2004;83:304\u201311. https:\/\/doi.org\/10.1097\/01.PHM.0000104680.28335.B9 PMID:15024333","DOI":"10.1097\/01.PHM.0000104680.28335.B9"},{"key":"160","doi-asserted-by":"crossref","unstructured":"[160] Jost WH,B\u00e4umer T,Laskawi R,Slawek J,Spittau B,Steffen A,<i>et al.<\/i> Therapy of sialorrhea with botulinum neurotoxin. Neurol Ther. 2019;8:273\u201388. https:\/\/doi.org\/10.1007\/s40120-019-00155-6 PMID:31542879","DOI":"10.1007\/s40120-019-00155-6"},{"key":"161","doi-asserted-by":"crossref","unstructured":"[161] Winterholler MGM,Erbguth FJ,Wolf S,Kat S. Botulinum toxin for the treatment of sialorrhoea in ALS: serious side effects of a transductal approach. J Neurol Neurosurg Psychiatry. 2001;70:417\u20138. https:\/\/doi.org\/10.1136\/jnnp.70.3.417 PMID:11248905","DOI":"10.1136\/jnnp.70.3.417"},{"key":"162","doi-asserted-by":"crossref","unstructured":"[162] Tugnoli V,Marchese Ragona R,Eleopra R,Quatrale R,Capone JG,Pastore A,<i>et al.<\/i> The role of gustatory flushing in Frey\u2019s syndrome and its treatment with botulinum toxin type A. Clin Auton Res. 2002;12:174\u20138. https:\/\/doi.org\/10.1007\/s10286-002-0026-x PMID:12269549","DOI":"10.1007\/s10286-002-0026-x"},{"key":"163","doi-asserted-by":"crossref","unstructured":"[163] Freni F,Gazia F,Stagno d\u2019Alcontres F,Galletti B,Galletti F. Use of botulinum toxin in Frey\u2019s syndrome. Clin Case Rep. 2019;7:482\u20135. https:\/\/doi.org\/10.1002\/ccr3.2019 PMID:30899477","DOI":"10.1002\/ccr3.2019"},{"key":"164","doi-asserted-by":"crossref","unstructured":"[164] Nasr MW,Jabbour SF,Sidaoui JA,Haber RN,Kechichian EG. Botulinum toxin for the treatment of excessive gingival display: a systematic review. Aesthet Surg J. 2016;36:82\u20138. https:\/\/doi.org\/10.1093\/asj\/sjv082 PMID:26254429","DOI":"10.1093\/asj\/sjv082"},{"key":"165","unstructured":"[165] Dinker S,Anitha A,Sorake A,Kumar K. Management of gummy smile with Botulinum Toxin Type-A: A case report. J Int Oral Health. 2014;6:111\u20135. PMID:24653614"},{"key":"166","doi-asserted-by":"crossref","unstructured":"[166] Bagis N,Barbaros R,Yildiz H. Application of botulinum toxin injection in symmetric and asymmetric gummy smile cases. International Journal of Experimental Dental Science. 2018;7:39\u201342. https:\/\/doi.org\/10.5005\/jp-journals-10029-1173","DOI":"10.5005\/jp-journals-10029-1173"},{"key":"167","doi-asserted-by":"crossref","unstructured":"[167] Perkins SW,Sandel HD IV. Anatomic considerations, analysis, and the aging process of the perioral region. Facial Plast Surg Clin North Am. 2007;15:403\u20137, v. https:\/\/doi.org\/10.1016\/j.fsc.2007.08.006 PMID:18005880","DOI":"10.1016\/j.fsc.2007.08.006"},{"key":"168","doi-asserted-by":"crossref","unstructured":"[168] Nigam PK,Nigam A. Botulinum toxin. Indian J Dermatol. 2010;55:8\u201314. https:\/\/doi.org\/10.4103\/0019-5154.60343 PMID:20418969","DOI":"10.4103\/0019-5154.60343"},{"key":"169","doi-asserted-by":"crossref","unstructured":"[169] Wu C,Xue F,Chang W,Lian Y,Zheng Y,Xie N,<i>et al.<\/i> Botulinum toxin type A with or without needle electromyographic guidance in patients with cervical dystonia. Springerplus. 2016;5:1292. https:\/\/doi.org\/10.1186\/s40064-016-2967-x PMID:27547666","DOI":"10.1186\/s40064-016-2967-x"},{"key":"170","doi-asserted-by":"crossref","unstructured":"[170] Benecke R. Clinical relevance of botulinum toxin immunogenicity. BioDrugs. 2012;26:e1\u20139. https:\/\/doi.org\/10.2165\/11599840-000000000-00000 PMID:22385408","DOI":"10.2165\/11599840-000000000-00000"},{"key":"171","doi-asserted-by":"crossref","unstructured":"[171] Dressler D. Clinical presentation and management of antibody-induced failure of botulinum toxin therapy. Mov Disord. 2004;19(suppl 8):S92\u2013100. https:\/\/doi.org\/10.1002\/mds.20022 PMID:15027060","DOI":"10.1002\/mds.20022"},{"key":"172","doi-asserted-by":"crossref","unstructured":"[172] Carr WW,Jain N,Sublett JW. Immunogenicity of botulinum toxin formulations: potential therapeutic implications. Adv Ther. 2021;38:5046\u201364. https:\/\/doi.org\/10.1007\/s12325-021-01882-9 PMID:34515975","DOI":"10.1007\/s12325-021-01882-9"},{"key":"173","doi-asserted-by":"crossref","unstructured":"[173] Nayyar P,Kumar P,Nayyar PV,Singh A. Botox: broadening the horizon of dentistry. J Clin Diagn Res. 2014;8:ZE25\u20139. PMID:25654058","DOI":"10.7860\/JCDR\/2014\/11624.5341"},{"key":"174","doi-asserted-by":"crossref","unstructured":"[174] Witmanowski H,B\u0142ochowiak K. The whole truth about botulinum toxin \u2013 a review. Postepy Dermatol Alergol. 2020;37:853\u201361. https:\/\/doi.org\/10.5114\/ada.2019.82795 PMID:33603602","DOI":"10.5114\/ada.2019.82795"},{"key":"175","doi-asserted-by":"crossref","unstructured":"[175] van Hulst K,Kouwenberg CV,Jongerius PH,Feuth T,van den Hoogen FJA,Geurts ACH,<i>et al.<\/i> Negative effects of submandibular botulinum neurotoxin A injections on oral motor function in children with drooling due to central nervous system disorders. Dev Med Child Neurol. 2017;59:531\u20137. https:\/\/doi.org\/10.1111\/dmcn.13333 PMID:27901263","DOI":"10.1111\/dmcn.13333"},{"key":"176","doi-asserted-by":"crossref","unstructured":"[176] Vartanian AJ,Dayan SH. Complications of botulinum toxin A use in facial rejuvenation. Facial Plast Surg Clin North Am. 2005;13:1\u201310. https:\/\/doi.org\/10.1016\/j.fsc.2004.04.008 PMID:15519923","DOI":"10.1016\/j.fsc.2004.04.008"},{"key":"177","unstructured":"[177] Small R. Botulinum toxin injection for facial wrinkles. Am Fam Physician. 2014;90:168\u201375. PMID:25077722"},{"key":"178","doi-asserted-by":"crossref","unstructured":"[178] Bai L,Peng X,Liu Y,Sun Y,Wang X,Wang X,<i>et al.<\/i> Clinical analysis of 86 botulism cases caused by cosmetic injection of botulinum toxin (BoNT). Medicine (Baltimore). 2018;97:e10659. https:\/\/doi.org\/10.1097\/MD.0000000000010659 PMID:30142749","DOI":"10.1097\/MD.0000000000010659"},{"key":"179","doi-asserted-by":"crossref","unstructured":"[179] Sharma M,Nazareth I,Petersen I. Observational studies of treatment effectiveness: worthwhile or worthless? Clin Epidemiol. 2018;11:35\u201342. https:\/\/doi.org\/10.2147\/CLEP.S178723 PMID:30588122","DOI":"10.2147\/CLEP.S178723"},{"key":"180","doi-asserted-by":"crossref","unstructured":"[180] Zwarenstein M,Treweek S,Gagnier JJ,Altman DG,Tunis S,Haynes B,<i>et al.<\/i>; CONSORT group; Pragmatic Trials in Healthcare (Practihc) group. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ. 2008;337:a2390. https:\/\/doi.org\/10.1136\/bmj.a2390 PMID:19001484","DOI":"10.1136\/bmj.a2390"}],"container-title":["Journal of Prosthodontic Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jpr\/67\/4\/67_JPR_D_22_00238\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T05:10:28Z","timestamp":1697260228000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jpr\/67\/4\/67_JPR_D_22_00238\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":180,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.2186\/jpr.jpr_d_22_00238","relation":{},"ISSN":["1883-1958","1883-9207"],"issn-type":[{"value":"1883-1958","type":"print"},{"value":"1883-9207","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023]]},"article-number":"JPR_D_22_00238"}}